Filing Analysis
Regulation FD Disclosure
Filed May 07, 2026
LOW
Cognition Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the 8-K filing.
Key Facts
- The filing reports financial results for the fiscal quarter ended March 31, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The press release was issued on May 7, 2026, and is included as Exhibit 99.1.
- The company is classified as an emerging growth company.
Regulation FD Disclosure
Filed Mar 26, 2026
LOW
Cognition Therapeutics announced its financial results for the fiscal year ended December 31, 2025, and furnished an updated investor presentation.
Key Facts
- The company reported financial results for the year ended December 31, 2025, on March 26, 2026.
- Furnished Exhibit 99.1: Press Release regarding financial results.
- Furnished Exhibit 99.2: Updated investor presentation for discussions with analysts and investors.
- The company maintains its status as an emerging growth company.
Regulation FD Disclosure
Filed Mar 02, 2026
LOW
Cognition Therapeutics announced plans to advance the development of its drug candidate, zervimesine, for the treatment of dementia with Lewy bodies (DLB) psychosis. The announcement was made via a press release on March 2, 2026.
Key Facts
- The company is advancing zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis.
- The announcement was filed under Item 8.01 (Other Events) on March 2, 2026.
- Cognition Therapeutics is classified as an emerging growth company.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.